 |
|
|
| |
Twice-Yearly Lenacapavir or Daily Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study
|
| |
| |
published today in NEJM, pdfs attached
Download the PDF here
Download the PDF here
with Editorial: The results of the PURPOSE 1 trial will raise scientific questions. For example, how can we address the diagnostic challenges of rare acute HIV-1 infection (as shown in the cabotegravir PrEP studies also now reported in the Journal4)?
What are the best tactics to combat the large number of coßncomitant sexually transmitted infections? What is the potential for emergent viral resistance? How do these data inform potential use for other groups at high risk for HIV infection? And how can we improve contraceptive options for women at high risk for HIV infection. Given the high pregnancy rate among Perhaps, however, the most critical question is how - more than a decade after PrEP was first approved in the United States and several years after the promising DISCOVER results among MSM5 - we have failed women at high risk for HIV infection for so long.
So now we have a PrEP product with high efficacy. That is great news for science but not (yet) great for women. Now, the imperative is to spend time, resources, and political will on access, implementation, and delivery. And that plan must include a mechanism to finance these drugs so that the women who have borne an unacceptably high HIV infection burden and who have volunteered for decades in studies of HIV prevention can reap the PrEP benefits and remain HIV free.
|
| |
|
|
|
|
|
